Please use this identifier to cite or link to this item:
|Title:||HPV & head and neck cancer: a descriptive update|
|Author:||Goon, Peter K.|
Stanley, Margaret A.
Bernal Sprekelsen, Manuel
Sudhoff, Holger H.
|Keywords:||Càncer de coll|
Càncer de cap
|Abstract:||The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1186/1758-3284-1-36|
|It is part of:||Head & Neck Oncology, 2009, vol. 1, p. 36|
|Appears in Collections:||Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)|
This item is licensed under a Creative Commons License